State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV

CLCGP, NGM (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153 Addeo A, Banna GL, Friedlaender A (2021) KRAS G12C mutations in NSCLC: from target to resistance. Cancers. https://doi.org/10.3390/cancers13112541 https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzellig-nsclc/@@guideline/html/index.html. Zugegriffen: 22. Juli 2022 S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. (2022) Chia PL, Mitchell P, Dobrovic A et al (2014) Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 6:423–432 Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282 Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739 Drilon A, Oxnard GR, Tan DSW et al (2020) Efficacy of Selpercatinib in. N Engl J Med 383:813–824 Du X, Yang B, An Q et al (2021) Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation 2:100103 Dziadziuszko R, Krebs MG, De Braud F et al (2021) Updated integrated analysis of the efficacy and safety of Entrectinib in locally advanced or metastatic. J Clin Oncol 39:1253–1263 Gadgeel SM, Shaw AT, Govindan R et al (2016) Pooled analysis of CNS response to Alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 34:4079–4085 Gainor JF, Curigliano G, Kim DW et al (2021) Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 22:959–969 Gainor JF, Dardaei L, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118–1133 Griesinger F, Eberhardt W, Nusch A et al (2021) Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315). Cancer Treat Res 152:174–184 Janning M, Süptitz J, Albers-Leischner C et al (2022) Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol 33:602–615 Katayama R, Kobayashi Y, Friboulet L et al (2015) Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 21:166–174 Kim DW, Tiseo M, Ahn MJ et al (2017) Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 35:2490–2498 Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139 Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388 Michels S, Massutí B, Schildhaus HU et al (2019) Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol 14:1266–1276 Michels SYF, Franklin J, Massuti B et al (2022) Crizotinib in ROS1-rearranged lung cancer (EUCROSS): updated overall survival. J Clin Oncol 40:9078–9078 Mok T, Camidge DR, Gadgeel SM et al (2020) Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056–1064 Mok TS, Wu YL, Ahn MJ et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640 Ou SI, Jänne PA, Leal TA et al (2022) First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced. J Clin Oncol. https://doi.org/10.1200/JCO.21.02752 Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500 Paik PK, Felip E, Veillon R et al (2020) Tepotinib in non-small-cell lung cancer with. N Engl J Med 383:931–943 Palma G, Khurshid F, Lu K et al (2021) Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precis Oncol 5:98 Park K, Haura EB, Leighl NB et al (2021) Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol 39:3391–3402 Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838 Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984–993 Planchard D, Kim TM, Mazieres J et al (2016) Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17:642–650 Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated. N Engl J Med 382:41–50 Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246 Russo A, Franchina T, Ricciardi G et al (2019) Heterogeneous responses to epidermal growth factor receptor (EGFR) Tyrosine Kinase inhibitors (TKis) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. https://doi.org/10.3390/ijms20061431 Scheffler M, Michels S, Nogova L (2022) Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. Inn Med 63:700–708 Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98 Schuette W, Schirmacher P, Eberhardt WE et al (2015) EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev 24:1254–1261 Shaw AT, Bauer TM, De Marinis F et al (2020) First-line lorlatinib or crizotinib in advanced. N Engl J Med 383:2018–2029 Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971 Shaw AT, Solomon BJ, Besse B et al (2019) Resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol 37:1370–1379 Skoulidis F, Li BT, Dy GK et al (2021) Sotorasib for lung cancers with. N Engl J Med 384:2371–2381 Solomon BJ, Martini J‑F, Shaw AT (2018) Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) in ROS1 kinase domain mutations. Ann Oncol 29 Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177 Soria JC, Tan DSW, Chiari R et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389:917–929 Stratmann JA, Michels S, Hornetz S et al (2018) Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J Cancer Res Clin Oncol 144:2457–2463 Sun TY, Niu X, Chakraborty A et al (2019) Lengthy progression-free survival and Intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J Thorac Oncol 14:e21–e24 Tan AC, Tan DSW (2022) Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 40:611–625 Wolf J, Seto T, Han JY et al (2020) Capmatinib in. N Engl J Med 383:944–957 Wu YL, Yang JC, Kim DW et al (2018) Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36:1405–1411 Zhao Y, Murciano-Goroff YR, Xue JY et al (2021) Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599:679–683